Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KLK7 | P49862 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.34 |
| ▸ | MET | P08581 | 3/20 | 0.34 |
| ▸ | RORC | P51449 | 2/20 | 0.33 |
| ▸ | BCL2 | P10415 | 1/20 | 0.33 |
| ▸ | YAP1 | P46937 | 1/20 | 0.33 |
| ▸ | PLAU | P00749 | 1/20 | 0.33 |
| ▸ | PLAT | P00750 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | TLR2 | O60603 | 1/20 | 0.32 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.32 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.32 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21626600 | 1.00 | MEN1 (0.35) | MEN1POLBKMT2AKLK7ALOX5 | |
| SCHEMBL21626592 | 0.94 | MEN1 (0.39) | MEN1POLBKMT2AKLK7ALOX5 | |
| SCHEMBL21626593 | 0.94 | MEN1 (0.39) | MEN1POLBKMT2AKLK7ALOX5 | |
| SCHEMBL20437151 | 0.91 | MEN1 (0.37) | MEN1POLBKMT2AKLK7ALOX5 | |
| SCHEMBL21626590 | 0.90 | MEN1 (0.36) | MEN1POLBKMT2AKLK7ALOX5 | |
| SCHEMBL23813319 | 0.89 | KMT2A (0.40) | MEN1POLBKMT2AKLK7 | |
| SCHEMBL20437153 | 0.85 | MEN1 (0.42) | MEN1POLBKMT2AKLK7ALOX5 | |
| SCHEMBL21626648 | 0.85 | MEN1 (0.43) | MEN1POLBKMT2AALOX5MET | |
| SCHEMBL28562102 | 0.85 | PTPN1 (0.41) | MEN1KMT2AYAP1PTPN1 | |
| SCHEMBL23799254 | 0.83 | MEN1 (0.41) | MEN1POLBKMT2AKLK7ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210284639-A1 | TYROSINE AMIDE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2021-09-16 | — | — | US | disclosed |
| WO-2020016129-A1 | TYROSINE AMIDE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2020-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210284639-A1 | TYROSINE AMIDE DERIVATIVES AS RHO- KINASE INHIBITORS | ROCK1, ROCK2, CIT | MEN1 4507/4885POLB 2768/4885KMT2A 1349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.